ArticleRheumatology (Oxford, England)2022
Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study.
Article in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Lower HLA-B27 positivity and heterogeneous late-onset case proportions across axial spondyloarthritis cohorts: a systematic review and meta-analysis.Rheumatology international · 2026Pooled it
- Surgical management and outcomes of ankylosing spondylitis fractures in adults: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Pooled it
- Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.Rheumatology (Oxford, England) · 2024Pooled it
- Pooled it
- Trial
- No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials.Arthritis research & therapy · 2026Trial
- Sexual Dysfunction in Women with Axial Spondyloarthritis: A Narrative Review Integrating Quantitative Evidence.Current rheumatology reports · 2026Review
- Article
- Evaluating Associations Between Ankylosing Spondylitis, Torque Teno Virus and Polymorphisms in Interleukin 6 and Vitamin D Receptor Genes.International journal of immunogenetics · 2026Article
- A Comprehensive Clinical Decision Support System for the Early Diagnosis of Axial Spondyloarthritis: Multi-Sequence MRI, Clinical Risk Integration, and Explainable Segmentation.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical characteristics, disease activity and psychosocial burden of axial spondyloarthritis in Jordan: a multicenter cross-sectional study.Scientific reports · 2026Observational
- Time and patient journey to axial spondyloarthritis diagnosis: a retrospective study in French primary care.Rheumatology (Oxford, England) · 2026Article
- Late onset axial spondyloarthritis presenting with fever of unknown origin. A case-based review.Rheumatology international · 2026Article
- Risk of anxiety disorder following ankylosing spondylitis, 2012-2023: a nationwide cohort study in South Korea.Frontiers in psychiatry · 2026Article
- Interrelations of disease activity, health-related quality of life, and mental health in axial spondyloarthritis: the Rheuma-VOR cohort.Frontiers in medicine · 2026Article
- Spondyloarthritis in Latin America: a difficult-to-diagnose challenge.Therapeutic advances in musculoskeletal disease · 2026Review
- NETosis-Related Biomarkers in Systemic Lupus Erythematosus, Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis: A Comparative Study.International journal of molecular sciences · 2025Article
- A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab.BMC rheumatology · 2025Article
- Comprehensive Oxidative Stress Profiling and Clinical Correlates in Spondyloarthritis: The Role of Glutathione Peroxidase and Modifiable Lifestyle Factors.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAge at onset is useful in identifying chronic back patients at an increased risk of axial SpA (axSpA). However, the majority of data on which the criterion of age at onset <45 years is based originates from Europe. Therefore it is unknown if this criterion applies in other parts of the world. We aimed to assess the age at onset of axSpA and its relationship with HLA-B27 and gender across the world.
methodsAnalyses were applied to patients from 24 countries across the world with an axSpA diagnosis and known age at onset of axial complaints. Cumulative probability plots were used to display the cumulative distribution of age at onset of axial symptoms. Linear regression models were built to assess the effect of HLA-B27 and gender on age at onset of axial symptoms.
resultsOf 2579 axSpA patients, 92% had an age at onset of axial symptoms <45 years, with only small variations across the geographical regions [Asia, n = 574 (94%); Europe and North America, n = 988 (92%); Latin America, n = 246 (89%); Middle East and North Africa, n = 771 (91%)]. Age at onset of axial symptoms was consistently lower in HLA-B27-positive patients {median 25 years [interquartile range (IQR) 19-32] vs 31 [IQR 22-39]} and male patients [median 25 years (IQR 19-33) vs 28 (IQR 21-37)], but in multivariable models an additional statistically significant effect of male gender independent of HLA-B27 was only found in Asia.
conclusionAround the world, the great majority of axSpA patients had an age at onset of axial disease of <45 years, with HLA-B27 and male gender associated with earlier disease onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.